A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)
Over the past few decades, advances in immunological knowledge have led to the identification of novel immune checkpoints, reinvigorating cancer immunotherapy. Immunotherapy, represented by immune checkpoint inhibitors, has become the leader in the precision treatment of cancer, bringing a new dawn...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2023-11-01
|
| Series: | Genes and Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352304222001556 |
| _version_ | 1797762828143165440 |
|---|---|
| author | Yan Lv Xiao Ma Yuxin Ma Yuxin Du Jifeng Feng |
| author_facet | Yan Lv Xiao Ma Yuxin Ma Yuxin Du Jifeng Feng |
| author_sort | Yan Lv |
| collection | DOAJ |
| description | Over the past few decades, advances in immunological knowledge have led to the identification of novel immune checkpoints, reinvigorating cancer immunotherapy. Immunotherapy, represented by immune checkpoint inhibitors, has become the leader in the precision treatment of cancer, bringing a new dawn to the treatment of most cancer patients. Galectin-9 (LGALS9), a member of the galectin family, is a widely expressed protein involved in immune regulation and tumor pathogenesis, and affects the prognosis of various types of cancer. Galectin-9 regulates immune homeostasis and tumor cell survival through its interaction with its receptor Tim-3. In the review, based on a brief description of the signaling mechanisms and immunomodulatory activities of galectin-9 and Tim-3, we summarize the targeted expression patterns of galectin-9 in a variety of malignancies and the promising mechanisms of anti-galectin-9 therapy in stimulating anti-tumor immune responses. |
| first_indexed | 2024-03-12T19:32:58Z |
| format | Article |
| id | doaj.art-db2ba96b646341eeb9d72630e0a571fb |
| institution | Directory Open Access Journal |
| issn | 2352-3042 |
| language | English |
| last_indexed | 2024-03-12T19:32:58Z |
| publishDate | 2023-11-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Genes and Diseases |
| spelling | doaj.art-db2ba96b646341eeb9d72630e0a571fb2023-08-02T04:24:26ZengKeAi Communications Co., Ltd.Genes and Diseases2352-30422023-11-0110623662382A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)Yan Lv0Xiao Ma1Yuxin Ma2Yuxin Du3Jifeng Feng4The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, ChinaDepartment of General Surgery, The Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, ChinaThe Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, China; Corresponding author.The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, China; Corresponding author.Over the past few decades, advances in immunological knowledge have led to the identification of novel immune checkpoints, reinvigorating cancer immunotherapy. Immunotherapy, represented by immune checkpoint inhibitors, has become the leader in the precision treatment of cancer, bringing a new dawn to the treatment of most cancer patients. Galectin-9 (LGALS9), a member of the galectin family, is a widely expressed protein involved in immune regulation and tumor pathogenesis, and affects the prognosis of various types of cancer. Galectin-9 regulates immune homeostasis and tumor cell survival through its interaction with its receptor Tim-3. In the review, based on a brief description of the signaling mechanisms and immunomodulatory activities of galectin-9 and Tim-3, we summarize the targeted expression patterns of galectin-9 in a variety of malignancies and the promising mechanisms of anti-galectin-9 therapy in stimulating anti-tumor immune responses.http://www.sciencedirect.com/science/article/pii/S2352304222001556Galectin-9Immune checkpoint inhibitorsImmunotherapyMonoclonal antibodyTim-3 |
| spellingShingle | Yan Lv Xiao Ma Yuxin Ma Yuxin Du Jifeng Feng A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9) Genes and Diseases Galectin-9 Immune checkpoint inhibitors Immunotherapy Monoclonal antibody Tim-3 |
| title | A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9) |
| title_full | A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9) |
| title_fullStr | A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9) |
| title_full_unstemmed | A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9) |
| title_short | A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9) |
| title_sort | new emerging target in cancer immunotherapy galectin 9 lgals9 |
| topic | Galectin-9 Immune checkpoint inhibitors Immunotherapy Monoclonal antibody Tim-3 |
| url | http://www.sciencedirect.com/science/article/pii/S2352304222001556 |
| work_keys_str_mv | AT yanlv anewemergingtargetincancerimmunotherapygalectin9lgals9 AT xiaoma anewemergingtargetincancerimmunotherapygalectin9lgals9 AT yuxinma anewemergingtargetincancerimmunotherapygalectin9lgals9 AT yuxindu anewemergingtargetincancerimmunotherapygalectin9lgals9 AT jifengfeng anewemergingtargetincancerimmunotherapygalectin9lgals9 AT yanlv newemergingtargetincancerimmunotherapygalectin9lgals9 AT xiaoma newemergingtargetincancerimmunotherapygalectin9lgals9 AT yuxinma newemergingtargetincancerimmunotherapygalectin9lgals9 AT yuxindu newemergingtargetincancerimmunotherapygalectin9lgals9 AT jifengfeng newemergingtargetincancerimmunotherapygalectin9lgals9 |